Synakis Awarded Overall Winner at ARVO 2025 Eye Pitch
May 3, 2025
Synakis has won the $25,000 1st place prize as the Overall Winner at the ARVO 2025 Eye Pitch.
Research on Long-acting Glaucoma Treatment Published in Advanced Materials
January 6, 2025
The research completed by Synakis’ Mickael Dang, Molly Shoichet, and co-authors enables the sustained delivery of an anti-glaucoma drug and a prolonged IOP-lowering effect for 7 weeks.
Synakis Selected to Present at 2025 OBIO Investment Summit
November 25, 2024
Synakis will be presenting as a pre-seed company in the Biotech session on February 5th, 2024.
Synakis Awarded Highest Scoring Pitch at the RESI Boston 2024 Innovator’s Pitch Challenge
September 27, 2024
Synakis was the highest scoring company in the Innovator’s Pitch Challenge medical devices session at RESI Boston 2024.
Synakis Admitted into CDL Biomedical Engineering Program
September 4, 2024
Synakis will participate in the in 2024/25 Creative Destruction Lab program in the Biomedical Engineering stream at CDL-Vancouver.
Synakis Featured on NGBiLab Podcast
June 13, 2024
On the podcast, Synakis’ Adam Forman and host Jim Wilson discuss Synakis’ mission to provide novel treatments for ocular diseases.
Synakis Selected to Present at MaRS Impact Health
May 10, 2024
Synakis’ Adam Forman will present at MaRS Impact Health during the Biotech Venture Showcase on June 13, 2024.
Synakis to Attend OCI DiscoveryX as Exhibitor
March 11, 2024
Synakis will be an exhibitor at the OCI DiscoveryX Conference on April 17th-18th, 2024.
Synakis Wins 1st Place in the Desjardins Startup Prize Late-Stage Pitch Competition
March 7, 2024
Synakis has won the $40,000 1st place prize at the 2024 Desjardins Startup Prize Pitch Competition in the late-stage category.
Synakis Selected as Late-Stage Finalist for Desjardins Startup Prize
January 22, 2024
Synakis will compete in the Desjardins Pitch Competition on March 7th, 2024 at the brand new Schwartz Reisman Innovation Campus where the winner will receive a $40,000 grand prize.
Synakis Selected to Present at 2024 OBIO Investment Summit
November 24, 2023
Synakis will be presenting as a pre-seed company at the Summit’s Early Technology Showcase on February 14th, 2024.
Synakis to Pitch at Lab2Market Deeptech Expo
September 25, 2023
Synakis will be participating in the Pitch Competition at Lab2Market’s Deeptech Expo on September 25th, 2023.
Synakis Invited to Canada SynBio 2023 Pitch Competition
June 1, 2023
The Canada SynBio 2023 Pitch Competition will take place on June 15th, 2023.
Synakis Accepted into Lab2Market Launch Program
May 19, 2023
The 12-week accelerator program will run from June-August 2023.
Synakis Invited to Join Collision’s Alpha Startup Program
May 10, 2023
Synakis will be participating in the Alpha Startup Program at Collision from June 26th-29th, 2023.
Synakis Profiled in UofT ChemEng News
April 18, 2023
Synakis’ Mickael Dang was interviewed for a profile on Synakis.
Synakis Wins TERMIS-AM 2023 Business Plan Competition
April 12, 2023
Synakis took home the top prize of $1000 at the TERMIS-AM 2023 Business Plan Competition. Synakis’ Mickael Dang presented the winning pitch at the TERMIS-AM 2023 Annual Conference in Boston.
Synakis Advances to Building a Biotech Venture Pitch Competition
March 31, 2023
Medicine by Design’s Building a Biotech Venture Pitch Competition will take place on May 2nd, 2023.
Synakis Joins H2i’s Accelera Program
January 6, 2023
Synakis has joined the Health Innovation Hub (H2i) Accelera 2.0 Program.
Synakis Selected for Medicine by Design’s Building a Biotech Venture Program
December 15, 2022
Synakis will join the 10-team program from January-March 2023.
Synakis Co-Founder Molly Shoichet Elected a Fellow of the National Academy of Inventors
December 8, 2022
Synakis co-founder Professor Molly Shoichet has been elected as a 2022 Fellow of the National Academy of Inventors (NAI).
Synakis Co-Founder Molly Shoichet Featured on CTV News
October 12, 2022
CTV News interviewed Synakis co-founder Professor Molly Shoichet about her research into treating retinal detachment, age-related macular degeneration, and retinitis pigmentosa.